MapLight Therapeutics, Inc. (MPLT)Healthcare | Biotechnology | Redwood City, United States | NasdaqGS
36.57 USD
-2.75
(-6.994%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 7:03 a.m. EDT
MapLight Therapeutics presents a classic biotech dilemma: a fortress balance sheet masking a lack of profitability and a precarious long-term trajectory. The company holds a massive cash reserve ($310M) against negligible debt, creating a theoretical runway that prevents immediate bankruptcy. However, the fundamentals are starkly negative, with significant losses on both assets and equity, and no revenue generation. The long-term rating remains neutral because the price history shows no sustained growth; despite the strong cash position, the market has not rewarded the business with a multi-year upward trend, indicating that investors view the current valuation as fair given the execution risks ahead. In the short term, the stock is stuck in a consolidation pattern, trading near its 50-day average but failing to break out decisively. The statistical forecast model offers a tiny upside prediction, but its reliability is virtually zero, rendering it useless for decision-making. More telling is the options flow, which screams caution. Traders are buying heavy put protection at lower strikes, betting on a potential stumble around the upcoming ZEPHYR trial readout. This defensive positioning suggests that while insiders may be accumulating, the broader speculative crowd is worried about the path forward. Until the company can demonstrate a clear path to profitability or a definitive positive catalyst that shifts the options skew, the investment case remains speculative. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.065273 |
| MSTL | 0.072331 |
| AutoETS | 0.072490 |
| AutoARIMA | 0.076030 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 5.99 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.023 |
| Excess Kurtosis | 0.29 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.398 |
| Market Cap | 1,658,291,328 |
| Forward P/E | -9.78 |
| Website | https://www.maplightrx.com |
As of July 11, 2026, 7:03 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 20 and 22.5) relative to calls. While there is some call volume at higher strikes (45), the overwhelming sentiment is hedging against a drop to the $20-$25 range, suggesting a fear of a failed clinical trial or capital burn issues rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9940022 |
| Address1 | 800 Chesapeake Drive |
| All Time High | 40.43 |
| All Time Low | 12.24 |
| Ask | 45.88 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 520,920 |
| Average Daily Volume3 Month | 387,506 |
| Average Volume | 387,506 |
| Average Volume10Days | 520,920 |
| Bid | 27.68 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 8.844 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 36.57 |
| Current Ratio | 22.91 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 39.28 |
| Day Low | 35.63 |
| Debt To Equity | 1.398 |
| Display Name | MapLight Therapeutics |
| Earnings Timestamp | 1,778,788,800 |
| Earnings Timestamp End | 1,786,651,200 |
| Earnings Timestamp Start | 1,786,651,200 |
| Ebitda | -209,468,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.463 |
| Enterprise Value | 1,353,769,344 |
| Eps Current Year | -5.14429 |
| Eps Forward | -3.74 |
| Eps Trailing Twelve Months | -4.41 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.7324 |
| Fifty Day Average Change | 5.837599 |
| Fifty Day Average Change Percent | 0.18994932 |
| Fifty Two Week Change Percent | 99.40022 |
| Fifty Two Week High | 40.43 |
| Fifty Two Week High Change | -3.8600006 |
| Fifty Two Week High Change Percent | -0.09547367 |
| Fifty Two Week Low | 12.24 |
| Fifty Two Week Low Change | 24.33 |
| Fifty Two Week Low Change Percent | 1.9877452 |
| Fifty Two Week Range | 12.24 - 40.43 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,761,571,800,000 |
| Float Shares | 13,346,139 |
| Forward Eps | -3.74 |
| Forward P E | -9.778075 |
| Free Cashflow | -95,698,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 133 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.51164 |
| Held Percent Institutions | 0.56014997 |
| Implied Shares Outstanding | 45,345,676 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-10-27 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. |
| Long Name | MapLight Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,658,291,328 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_605975835 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -199,480,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,658,291,371 |
| Number Of Analyst Opinions | 12 |
| Open | 38.13 |
| Operating Cashflow | -163,764,992 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 617 984 6300 |
| Previous Close | 39.32 |
| Price Eps Current Year | -7.108853 |
| Price Hint | 2 |
| Price To Book | 4.135007 |
| Profit Margins | 0.0 |
| Quick Ratio | 21.712 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.15385 |
| Region | US |
| Regular Market Change | -2.75 |
| Regular Market Change Percent | -6.9939 |
| Regular Market Day High | 39.28 |
| Regular Market Day Low | 35.63 |
| Regular Market Day Range | 35.63 - 39.28 |
| Regular Market Open | 38.13 |
| Regular Market Previous Close | 39.32 |
| Regular Market Price | 36.57 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 509,840 |
| Return On Assets | -0.49505 |
| Return On Equity | -0.80953 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 42,618,165 |
| Shares Percent Shares Out | 0.056799997 |
| Shares Short | 2,577,722 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,562,112 |
| Short Name | MapLight Therapeutics, Inc. |
| Short Percent Of Float | 0.1172 |
| Short Ratio | 5.58 |
| Source Interval | 15 |
| State | CA |
| Symbol | MPLT |
| Target High Price | 60.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 41.5 |
| Target Median Price | 42.5 |
| Total Cash | 310,112,992 |
| Total Cash Per Share | 6.839 |
| Total Debt | 5,591,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 22.28551 |
| Two Hundred Day Average Change | 14.284491 |
| Two Hundred Day Average Change Percent | 0.6409766 |
| Type Disp | Equity |
| Volume | 509,840 |
| Website | https://www.maplightrx.com |
| Zip | 94,063 |